SCHEMBL24650780

SCHEMBL24650780

COc1cccc2c1C(CC(=O)O)C(N)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AADAT Q8N5Z0 1/20 0.42
HTR1A P08908 5/20 0.41
DRD2 P14416 1/20 0.40
DRD3 P35462 1/20 0.40
HTR2A P28223 1/20 0.40
MTNR1A P48039 5/20 0.39
MTNR1B P49286 5/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
CYP1A2 P05177 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CTH P32929 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24650766 0.89 GLA (0.45) CYP1A2MAPTCYP2C9ALDH1A1
SCHEMBL24650905 0.88 HTR1A (0.43) AADATHTR1ADRD2DRD3HTR2A
SCHEMBL24651120 0.86 HTR1A (0.42) AADATHTR1ADRD2DRD3HTR2A
SCHEMBL24651122 0.84 HTR1A (0.40) AADATHTR1ADRD2DRD3HTR2A
SCHEMBL24650901 0.84 HTR1A (0.40) AADATHTR1ADRD2DRD3HTR2A
SCHEMBL9035471 0.83 SMN1; SMN2 (0.42) HTR1AMTNR1AMTNR1BCA12CA1
SCHEMBL24650867 0.83 PTGFR (0.40) AADATHTR1ADRD2DRD3HTR2A
SCHEMBL9035210 0.82 MTNR1A (0.41) HTR1AHTR2AMTNR1AMTNR1BCA12
SCHEMBL24651137 0.80 HTR1A (0.44) AADATHTR1AHTR2AMTNR1AMTNR1B
SCHEMBL24650839 0.80 AADAT (0.44) AADATHTR1ADRD2DRD3HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022238507-A1 THERAPEUTIC AMINOINDANE COMPOUNDS AND COMPOSITIONS AWAKN LS EUROPE HOLDINGS LIMITED (IE) 2022-11-17 WO disclosed